News
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...
Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...
With $30 million in state grants, pharmaceutical giant Merck is building a factory to employ at least 375 at an old DuPont ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback